Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease

JACC: Cardiovascular Imaging

Volumn 6, Issue 8, 2013, Pages 877-885

  Drafts, Brandon C ^a   Twomley, Katie M ^a   D'Agostino Jr , Ralph ^a   Lawrence, Julia ^a   Avis, Nancy ^a   Ellis, Leslie R ^a   Thohan, Vinay ^a   Jordan, Jennifer ^a   Melin, Susan A ^a   Torti, Frank M ^a   Little, William C ^a   Hamilton, Craig A ^a   Hundley, W Gregory ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

cardio oncology; cardiotoxicity; chemotherapy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXORUBICIN; GADOLINIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN I; VASODILATOR AGENT;

ADULT; AGED; AORTIC PULSE WAVE VELOCITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CIRCUMFERENTIAL STRAIN; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE VOLUME; HUMAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE WAVE; QUALITY OF LIFE;

ANTH-BC; ANTHRACYCLINE-BASED CHEMOTHERAPY; B-TYPE NATRIURETIC PEPTIDE; BNP; CARDIAC MAGNETIC RESONANCE; CARDIO-ONCOLOGY; CARDIOTOXICITY; CARDIOVASCULAR; CHEMOTHERAPY; CMR; CV; ECHO TIME; LEFT VENTRICULAR EJECTION FRACTION; LEFT VENTRICULAR END-DIASTOLIC VOLUME; LEFT VENTRICULAR END-SYSTOLIC VOLUME; LVEDV; LVEF; LVESV; MINNESOTA LIVING WITH HEART FAILURE QUESTIONNAIRE; MLHFQ; PULSE WAVE VELOCITY; PWV; QOL; QUALITY OF LIFE; REPETITION TIME; TE; TNI; TR; TROPONIN I;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; LEUKEMIA; LYMPHOMA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PULSE WAVE ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; STROKE VOLUME; TIME FACTORS; TROPONIN I; VASCULAR STIFFNESS; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84883348349     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2012.11.017     Document Type: Article

References (32)

1. X.L. Du, E.E. Fox, and D. Lai Competing causes of death for women with breast cancer and change over time from 1975 to 2003 Am J Clin Oncol 31 2008 105 116
2. M.J. Hooning, A. Botma, and B.M. Aleman Long-term risk of cardiovascular disease in 10-year survivors of breast cancer J Natl Cancer Inst 99 2007 365 375
3. A.J. Swerdlow, C.D. Higgins, and P. Smith Myocardial infarction mortality risk after treatment for Hodgkin's disease: a collaborative British cohort study J Natl Cancer Inst 99 2007 206 214
4. P.K. Singal, and N. Iliskovic Doxorubicin-induced cardiomyopathy N Engl J Med 339 1998 900 905
5. T. Eschenhagen, T. Force, and M.S. Ewer Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology Eur J Heart Fail 13 2011 1 10
6. P. Rerkpattanapipat, R.B. D'Agostino Jr., and K.M. Link Location of arterial stiffening differs in those with impaired fasting glucose versus diabetes: implications for left ventricular hypertrophy from the Multi-Ethnic Study of Atherosclerosis Diabetes 58 2009 946 953
7. S.R. Heckbert, W. Post, and G.D. Pearson Traditional cardiovascular risk factors in relation to left ventricular mass, volume, and systolic function by cardiac magnetic resonance imaging: the Multiethnic Study of Atherosclerosis J Am Coll Cardiol 48 2006 2285 2292
8. M.L. Shehata, S. Cheng, N.F. Osman, D.A. Bluemke, and J.A. Lima Myocardial tissue tagging with cardiovascular magnetic resonance J Cardiovasc Magn Reson 11 2009 55
9. S. Sampath, J.A. Derbyshire, E. Atalar, N.F. Osman, and J.L. Prince Real-time imaging of two-dimensional cardiac strain using a harmonic phase magnetic resonance imaging (HARP-MRI) pulse sequence Magn Reson Med 50 2003 154 163
10. N. Chaosuwannakit, R. D'Agostino Jr., and C.A. Hamilton Aortic stiffness increases upon receipt of anthracycline chemotherapy J Clin Oncol 28 2010 166 172
11. R.J. Kim, E. Wu, and A. Rafael The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction N Engl J Med 343 2000 1445 1453
12. J. John, D.B. Woodward, and Y. Wang Troponin-I as a prognosticator of mortality in severe sepsis patients J Crit Care 25 2010 270 275
13. G. Daugaard, U. Lassen, and P. Bie Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction Eur J Heart Fail 7 2005 87 93
14. T. Keller, T. Zeller, and D. Peetz Sensitive troponin I assay in early diagnosis of acute myocardial infarction N Engl J Med 361 2009 868 877
15. T.S. Rector A conceptual model of the quality of life in relation to heart failure J Cardiac Failure 11 2005 173 176
16. D.L. Keefe Anthracycline-induced cardiomyopathy Semin Oncol 28 2001 2 7
17. S. Yusuf, K.K. Teo, and J. Pogue Telmisartan, ramipril, or both in patients at high risk of vascular events N Engl J Med 358 2008 1547 1559
18. M. Jessup, W.T. Abraham, and D.E. Casey 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults Circulation 119 2009 1977 2016
19. R.S. Bhatia, J.V. Tu, and D.S. Lee Outcome of heart failure with preserved ejection fraction in a population-based study N Engl J Med 355 2006 260 269
20. Y. Cheung, W.J. Hong, G.C. Chan, S.J. Wong, and S.Y. Ha Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy Heart 96 2010 1137 1141
21. T. Stanton, R. Leano, and T.H. Marwick Prediction of all cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring Circ Cardiovasc Imaging 2 2009 356 364
22. N.G. Bellenger, L.C. Davies, J.M. Francis, A.J. Coats, and D.J. Pennell Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance J Cardiovasc Magn Reson 2 2000 271 278
23. C.L. Hung, A. Verma, and H. Uno Longitudinal and circumferential strain rate, left ventricular remodeling, and prognosis after myocardial infarction J Am Coll Cardiol 56 2010 1812 1822
24. S. Laurent, P. Boutouyrie, and R. Asmar Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients Hypertension 37 2001 1236 1241
25. P. Boutouyrie, Al Tropeano, and R. Asmar Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study Hypertension 39 2002 10 15
26. J.J. Green, J.S. Berger, C.M. Kramer, and M. Salerno Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy J Am Coll Cardiol Img 5 2012 370 377
27. R.D. Perel, R.E. Slaughter, and W.E. Strugnell Subendocardial late gadolinium enhancement in two patients with anthracycline cardiotoxicity following treatment for Ewing's sarcoma J Cardiovasc Magn Reson 8 2006 789 791
28. D. Cardinale, M.T. Sandri, and A. Colombo Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy Circulation 109 2004 2749 2754
29. T.S. Rector, P.E. Carson, and I.S. Anand Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the Minnesota Living with Heart Failure Questionnaire in the Irbesartan in Heart Failure with Perserved Systolic Function (I-PRESERVE) Trial Circ Heart Fail 5 2012 217 225
30. M.A. Quinones, B.H. Greenberg, and H.A. Kopelen Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction J Am Coll Cardiol 35 2000 1237 1244
31. B. Dahlof Cardiovascular disease risk factors: epidemiology and risk assessment Am J Cardiol Suppl 1 2010 3A 9A
32. I. Germanakis, N. Anagnostatou, and M. Kalmanti Troponins and natriuretic peptides in the monitoring of anthracycline cardiotoxicity Pediatr Blood Cancer 51 2008 327 333